SCHEMBL1384296

SCHEMBL1384296

COc1cc(OC)cc(N2CCN(C(=O)c3sc(O)nc3-c3ccccc3)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
TP53 P04637 2/20 0.50
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 2/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
MAPT P10636 4/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
POLB P06746 1/20 0.49
CCKAR P32238 3/20 0.47
GAA P10253 3/20 0.47
TRPV4 Q9HBA0 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
CASP1 P29466 1/20 0.45
HTT P42858 1/20 0.45
SMO Q99835 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1380918 0.89 LMNA (0.50) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL1381703 0.89 TP53 (0.53) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL1381524 0.88 POLB (0.52) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL1383651 0.81 TRPV4 (0.49) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL1380400 0.81 LMNA (0.51) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL1383839 0.81 LMNA (0.48) LMNATSHRMAPTPOLBKMT2A
SCHEMBL1381055 0.77 LMNA (0.52) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL6503239 0.76 KDM4E (0.56) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL5750395 0.76 SMN1; SMN2 (0.50) LMNATP53ALDH1A1KDM4EHPGD
SCHEMBL1381201 0.75 ALDH1A1 (0.46) LMNATP53ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4805813-B2 2011-11-02 JP claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP claimed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US claimed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC LMNA 3596/4885TP53 19/4885ALDH1A1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.